Literature DB >> 4046632

4-Hydroperoxycyclophosphamide inhibits proliferation by human granulocyte-macrophage colony-forming cells (GM-CFC) but spares more primitive progenitor cells.

M Y Gordon, J M Goldman, E C Gordon-Smith.   

Abstract

Despite its considerable toxicity to haemopoietic colony-forming cells, 4-hydroperoxycyclophosphamide (4-HC) has successfully been used to purge marrow of leukaemic cells before it is used to rescue patients from high-dose chemoradiotherapy. These conflicting observations indicate that haemopoietic progenitor cells that are not detected by the established colony-forming assays survive exposure to 4-HC and repopulate the marrow. The recent finding that murine spleen colony-forming cells (CFU-S) are resistant to 4-HC [Porcellini A, et al. (1983) Expl Hemat. 11 (suppl 14) 331 (abstract)] [14] also indicates that sensitivity to 4-HC can be used to distinguish primitive progenitor cells from committed progenitor cells. As part of a study on the nature of a population of blast colony-forming cells in human bone marrow, we tested their sensitivity to 4-HC to see whether they also are spared by the drug. We found that 4-HC had much less effect on the blast colony-forming cells than on the granulocyte-macrophage colony-forming cells (GM-CFC). This result suggests that the blast-colony-forming cells may be early human haemopoietic progenitor cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4046632     DOI: 10.1016/0145-2126(85)90072-4

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  16 in total

Review 1.  Bone marrow purging with mafosfamide--a critical survey.

Authors:  H Sindermann; M Peukert; P Hilgard
Journal:  Blut       Date:  1989-11

Review 2.  Hematopoietic stem cells.

Authors:  Robert G Hawley; Ali Ramezani; Teresa S Hawley
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

Review 3.  Stem cell plasticity: a rare cell, not a rare event.

Authors:  Yoon-Young Jang; Saul J Sharkis
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

4.  Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis.

Authors:  Daniel B Drachman; Robert N Adams; Rong Hu; Richard J Jones; Robert A Brodsky
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

5.  Characterization of a human hematopoietic progenitor cell capable of forming blast cell containing colonies in vitro.

Authors:  J Brandt; N Baird; L Lu; E Srour; R Hoffman
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

6.  Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity.

Authors:  R W Storms; A P Trujillo; J B Springer; L Shah; O M Colvin; S M Ludeman; C Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

7.  An Update on Myasthenic Crisis.

Authors:  Shafiuddin Ahmed; Jawad F Kirmani; Nazli Janjua; Ammar Alkawi; Ismail Khatri; Abutaher M Yahia; Nizar Souyah; Adnan I Qureshi
Journal:  Curr Treat Options Neurol       Date:  2005-03       Impact factor: 3.598

Review 8.  Advances in complex multiparameter flow cytometry technology: Applications in stem cell research.

Authors:  Frederic Preffer; David Dombkowski
Journal:  Cytometry B Clin Cytom       Date:  2009-09       Impact factor: 3.058

Review 9.  Cyclophosphamide and cancer: golden anniversary.

Authors:  Ashkan Emadi; Richard J Jones; Robert A Brodsky
Journal:  Nat Rev Clin Oncol       Date:  2009-09-29       Impact factor: 66.675

Review 10.  Circulating progenitor cells and scleroderma.

Authors:  Richard H Gomer
Journal:  Curr Rheumatol Rep       Date:  2008-07       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.